BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
‘Risk children’s lives for some extra manpower’: IRGC recruits 12 year olds to fill personnel gaps - 2Tear gas and arrests: Iranian regime continues crackdown on protesters amid economic unrest
- 3Floods, Landslides Triggered By Heavy Rain In Afghanistan Leave 77 Dead In 10 days, Authorities Say
- 4Remote Headphones: Improve Your Sound Insight
- 5Germany's Bundestag extends two armed forces missions abroad
- Palestinian infant freezes to death in Gaza as Israel keeps blocking aid
- 4 Excellent Remote Headphones of 2024
- Manual for Notorious Fragrances: Immortal Aromas
- 5 Arising Professions in Environmentally friendly power
- Al-Sharaa denies he called for 80% of Syrians to return from Germany
- Countdown to Artemis II: What to know about NASA's moon mission
- The Magnificence of Do-It-Yourself Skincare: Regular Recipes and Tips
- Instructions to Keep up with Your Traded Teeth for Life span
- Really focusing on Succulents: Tips and Procedures
